Sector News

Perrigo spurns second offer from Mylan

April 27, 2015
Life sciences
The Perrigo-Mylan-Teva takeover saga has taken another turn after Perrigo again spurned Mylan’s advances, rejecting a second bid from the generics giant.
 
Desperate to protect itself from a Teva takover, Mylan has laid a new bid on the table for Perrigo of $60 cash and 2.2 of its share’s for every remaining share in the Dublin, Ireland-based firm. This, it claims, values the deal at around $222 per Perrigo share.
 
However, Perrigo has taken a different stance on Mylan’s new proposal, arguing that, based in its own calculations, which uses Mylan’s lower share price before rumours of Teva’s interest started to grow, the offer actually only equates to $188 a share.
 
This, it notes, falls under the $205 a share proposed by Mylan early last week. As such, Perrigo’s Board “strongly advised” the firm’s shareholders “to take no action in relation to the offer”.
 
Mylan is yet to respond to Teva’s $40-billion takeover bid, but indications are that it seems reluctant to accept.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

October 17, 2021

Colorcon acquires a majority share in Ideal Cures Pvt. Ltd., India

Life sciences

Ideal Cures will operate as a fully independent entity within Colorcon. Their business complements Colorcon’s position in the Indian pharmaceutical market with a strong presence in the domestic generic sector comprised of long-standing customer relationships sustained by innovative and customized solutions.

October 17, 2021

Barriers exist, but participation urgent in breast cancer clinical trials: report

Life sciences

Across four new breast cancer treatments approved by the FDA last year, 2% to 9% of patients in clinical trials for the drugs were Black Americans and 0% to 9% were Hispanic, according to a new report from Breastcancer.org.

October 17, 2021

Danish consortium acquires part of Jernbanebyen to create one of the world’s healthiest urban villages

Life sciences

The southern section of Jernbanebyen in central Copenhagen has a new owner. The Baneby Consortium, comprising NREP, Novo Holdings and Industriens Pension, has bought the land from Freja Ejendomme. The ambition is to create a green, partly car-free environment that will also be one of the healthiest in the world. 

Send this to a friend